ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

SILIQ
Psoriasis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

SILIQ Rx

Generic Name and Formulations:
Brodalumab 210mg/1.5mL; soln for SC inj; preservative-free.

Company:
Valeant Pharmaceuticals, Inc

Therapeutic Use:

Indications for SILIQ:

Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and unresponsive to other systemic therapies.

Adult:

Give by SC inj into thigh, abdomen (except for area around navel), outer area of upper arm; rotate inj sites. 210mg at Weeks 0, 1, and 2 followed by 210mg every 2 weeks. If adequate response not achieved after 12–16 weeks, consider discontinuing.

Children:

Not established.

Contraindications:

Crohn’s disease.

Warnings/Precautions:

Must enroll patients in the Siliq REMS program; advise patients of the risk of suicidal ideation and behavior. History of depression or suicidality. May increase risk of infections. Chronic or history of recurrent infection: consider the risks and benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue until resolves. Evaluate for TB infection prior to initiating; monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. History of latent or active TB; consider anti-TB therapy prior to initiation. Discontinue if Crohn’s disease develops. Pregnancy. Nursing mothers.

Interactions:

Avoid concomitant live vaccines. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.

Pharmacological Class:

Interleukin-17A antagonist.

Adverse Reactions:

Arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, inj site reactions, influenza, neutropenia, tinea infections.

REMS:

YES

Generic Availability:

NO

How Supplied:

Single-dose prefilled syringes—2

Sign Up for Free e-Newsletters